Joint venture · GCC · Announced 15 Apr 2026
Jerusalem Pharmaceuticals → Saudi investors
Palestine's Jerusalem Pharmaceuticals Group agreed to build a manufacturing plant in Saudi Arabia with Saudi investors, holding 70%, alongside a bonus share issue that doubles its capital to US$36 million.
Parties: Jerusalem Pharmaceuticals Group (Palestine) → Saudi investors (not named) (Saudi Arabia)
- Deal type
- Joint venture
- Value
- Undisclosed
- Territory
- Saudi Arabia
- Therapeutic area
- Multi-therapy
- Asset
- Pharmaceutical manufacturing plant
- Announced
- 15 Apr 2026
Our analysis
Why this matters
On 15 April 2026, Jerusalem Pharmaceuticals Group (مجموعة القدس للمستحضرات الطبية) announced at its general assemblies an agreement to establish a pharmaceutical plant in Saudi Arabia in partnership with Saudi investors, with the group holding 70% and the Saudi partners 30%. The partners were not named and no investment amount or completion date was given. Shareholders also approved raising capital by US$18 million to US$36 million through capitalising retained earnings (a bonus issue), and a cash dividend of US$2.7 million.
The group reported 2025 net sales of US$48.95 million and net profit of US$10.26 million, and says it exports generics to 27 countries. It also opened a scientific office in the UAE and plans more than 18 new products.
The full analysis is free to read with a work email on this page.
Source: Raya (Palestine)